Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M 4 PAM VU0467154

• Published in: Neuropharmacology Vol. 128; p. 492
• Main Authors: Gould, Robert W, Grannan, Michael D, Gunter, Barak W, Ball, Jacob, Bubser, Michael, Bridges, Thomas M, Wess, Jurgen, Wood, Michael W, Brandon, Nicholas J, Duggan, Mark E, Niswender, Colleen M, Lindsley, Craig W, Conn, P Jeffrey, Jones, Carrie K
• Format: Journal Article
• Language: English
• Published: England 01.01.2018
• Subjects: Allosteric Regulation - drug effects; Animals; Antipsychotic Agents - metabolism; Antipsychotic Agents - therapeutic use; Brain - drug effects; Cognition Disorders - drug therapy; Cognition Disorders - etiology; Discrimination, Psychological - drug effects; Disease Models, Animal; Dizocilpine Maleate - toxicity; Dose-Response Relationship, Drug; Hyperkinesis - chemically induced; Hyperkinesis - drug therapy; Male; Memory Disorders - chemically induced; Memory Disorders - drug therapy; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyridazines - metabolism; Pyridazines - therapeutic use; Receptor, Muscarinic M4 - genetics; Schizophrenia - complications; Schizophrenia - drug therapy; Schizophrenia - genetics; Thiophenes - metabolism; Thiophenes - therapeutic use; M muscarinic acetylcholine receptor; MK-801; Positive allosteric modulator; Cognitive enhancement; Antipsychotic-like activity; VU0467154
• ISSN: 1873-7064
• DOI: 10.1016/j.neuropharm.2017.07.013

Although selective activation of the M muscarinic acetylcholine receptor (mAChR) subtype has been shown to improve cognitive function in animal models of neuropsychiatric disorders, recent evidence suggests that enhancing M mAChR function can also improve memory performance. Positive allosteric modulators (PAMs) targeting the M mAChR subtype have shown therapeutic potential for the treatment of multiple symptoms observed in schizophrenia, including positive and cognitive symptoms when assessed in acute preclinical dosing paradigms. Since the cholinergic system has been implicated in multiple stages of learning and memory, we evaluated the effects of repeated dosing with the highly selective M PAM VU0467154 on either acquisition and/or consolidation of learning and memory when dosed alone or after pharmacologic challenge with the N-methyl-d-aspartate subtype of glutamate receptors (NMDAR) antagonist MK-801. MK-801 challenge represents a well-documented preclinical model of NMDAR hypofunction that is thought to underlie some of the positive and cognitive symptoms observed in schizophrenia. In wildtype mice, 10-day, once-daily dosing of VU0467154 either prior to, or immediately after daily testing enhanced the rate of learning in a touchscreen visual pairwise discrimination task; these effects were absent in M mAChR knockout mice. Following a similar 10-day, once-daily dosing regimen of VU0467154, we also observed 1) improved acquisition of memory in a cue-mediated conditioned freezing paradigm, 2) attenuation of MK-801-induced disruptions in the acquisition of memory in a context-mediated conditioned freezing paradigm and 3) reversal of MK-801-induced hyperlocomotion. Comparable efficacy and plasma and brain concentrations of VU0467154 were observed after repeated dosing as those previously reported with an acute, single dose administration of this M PAM. Together, these studies are the first to demonstrate that cognitive enhancing and antipsychotic-like activity are not subject to the development of tolerance following repeated dosing with a selective M PAM in mice and further suggest that activation of M mAChRs may modulate both acquisition and consolidation of memory functions.